dc.contributor.author |
Podzamczer Palter, Daniel |
dc.contributor.author |
Rozas, Nerea |
dc.contributor.author |
Domingo, Pere |
dc.contributor.author |
Ocampo, Antonio |
dc.contributor.author |
van den Eynde, Eva |
dc.contributor.author |
Deig, Elisabeth |
dc.contributor.author |
Vergara, Antonio |
dc.contributor.author |
Knobel, Hernando |
dc.contributor.author |
Pasquau, Juan |
dc.contributor.author |
Antela, Antonio |
dc.contributor.author |
Crespo, Manuel |
dc.contributor.author |
Clotet i Sala, Bonaventura |
dc.contributor.author |
Muñoz, Jessica |
dc.contributor.author |
Fernandez, Pedro |
dc.contributor.author |
Geijo, Paloma |
dc.contributor.author |
Rodríguez de Castro, Eduardo |
dc.contributor.author |
Diz, Julio |
dc.contributor.author |
Casado, Araceli |
dc.contributor.author |
Torres, Covadonga |
dc.date |
2018-11-21T14:01:39Z |
dc.date |
2018-11-21T14:01:39Z |
dc.date |
2014-11-01 |
dc.date |
2018-07-24T12:36:32Z |
dc.identifier.uri |
http://hdl.handle.net/2445/126289 |
dc.format |
2 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Wiley |
dc.relation |
Reproducció del document publicat a: https://doi.org/10.7448/IAS.17.4.19814 |
dc.relation |
Journal of the International AIDS Society, 2014, vol. 17, supl. 3 |
dc.relation |
https://doi.org/10.7448/IAS.17.4.19814 |
dc.rights |
cc by (c) Podzamczer Palter et al., 2014 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by/3.0/es/ |
dc.subject |
Infeccions per VIH |
dc.subject |
Antiretrovirals |
dc.subject |
HIV infections |
dc.subject |
Antiretroviral agents |
dc.title |
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF
due to previous intolerance to CART. Interim analysis of the PROSTR
study |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
Introduction: Tolerability and convenience are crucial aspects for the long-term success of combined antiretroviral therapy
(cART). The aim of this study was to investigate the impact in routine clinical practice of switching to the single tablet regimen
(STR) RPV/FTC/TDF in patients with intolerance to previous cART, in terms of patients’ well-being, assessed by several validated
measures.
Methods: Prospective, multicenter study. Adult HIV-infected patients with viral load under 1.000 copies/mL while receiving a
stable ART for at least the last three months and switched to RPV/FTC/TDF due to intolerance of previous regimen, were
included. Analyses were performed by ITT. Presence/magnitude of symptoms (ACTG-HIV Symptom Index), quality of life (EQ-5D,
EUROQoL & MOS-HIV), adherence (SMAQ), preference of treatment and perceived ease of medication (ESTAR) through 48
weeks were performed.
Results: Interim analysis of 125 patients with 16 weeks of follow up was performed. 100 (80%) were male, mean age 46 years.
Mean CD4 at baseline was 629.59307.29 and 123 (98.4%) had viral load B50 copies/mL; 15% were HCV co-infected. Ninety
two (73.6%) patients switched from a NNRTI (84.8% from EFV/FTC/TDF) and 33 (26.4%) from a PI/r. The most frequent reasons
for switching were psychiatric disorders (51.2%), CNS adverse events (40.8%), gastrointestinal (19.2%) and metabolic disorders
(19.2%). At the time of this analysis (week 16), four patients (3.2%) discontinued treatment: one due to adverse events, two
virologic failures and one with no data. A total of 104 patients (83.2%) were virologically suppressed (B50 copies/mL). The
average degree of discomfort in the ACTG-HIV Symptom Index significantly decreased from baseline (21915.55) to week 4
(10.89912.36) & week 16 (10.81912.62), pB0.001. In all the patients, quality of life tools showed a significant benefit in wellbeing
of the patients (Table 1). Adherence to therapy significantly and progressively increased (SMAQ) from baseline (54.4%) to
week 4 (68%), pB0.001 and to week 16 (72.0%), pB0.001.
Conclusions: Switching to RPV/FTC/TDF from another ARV regimen due to toxicity, significantly improved the quality of life of
HIV-infected patients, both in mental and physical components, and improved adherence to therapy while maintaining a good
immune and virological response. |